Filing Scope and Business Context
The provided filing is Olivia Ventures, Inc.’s Form 10-K for the fiscal year ended March 31, 2020, not a Compass Therapeutics, Inc. filing or a 2019 Q4 report. Olivia Ventures was a Delaware blank-check and shell company formed to pursue a merger or acquisition and had no active operating business or revenue since inception.
As of March 31, 2020, the Company had nominal assets, no employees other than its officers, no owned or leased property, and two directors who controlled all 5,000,000 outstanding common shares.
Financial Performance and Position
| Metric | Year ended March 31, 2020 | Year ended March 31, 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expenses | $32,105 | $32,759 |
| Interest expense | $5,378 | $3,278 |
| Net loss | $37,483 | $36,037 |
| Basic and diluted loss per share | $0.01 | $0.01 |
| Cash from operating activities | $(32,106) | $(32,759) |
| Cash from financing activities | $30,985 | $37,625 |
| Cash at period end | $3,745 | $4,866 |
| Total current liabilities | $111,817 | $75,455 |
| Stockholders’ deficit | $108,072 | $70,589 |
The Company had no operating margin because it generated no revenue. Its losses consisted primarily of legal, accounting, audit, professional, general and administrative, and interest costs. No dividends were paid or expected before a business combination.
Debt consisted principally of a related-party promissory note payable to director and stockholder Mark Tompkins. The balance was $111,817 at March 31, 2020, including $103,110 of advances and $8,707 of accrued interest. The note bears interest at 6% annually and becomes subject to an 18% default rate beginning five days after a defined default date.
Material Changes Versus the Prior Period
- Net loss increased by $1,446, or approximately 4%, from $36,037 to $37,483.
- Interest expense increased by $2,100, reflecting the growth in related-party borrowings.
- Current liabilities increased by $36,362, or approximately 48%, from $75,455 to $111,817.
- Cash declined by $1,121, from $4,866 to $3,745, despite $30,985 of financing proceeds.
- Stockholders’ deficit increased by $37,483 to $108,072, driven by the fiscal-year net loss.
- Operating cash use improved slightly by $653, while financing proceeds declined by $6,640.
Outlook, Proposed Transaction, and Risks
Management planned to continue searching for a business combination but had not identified a definitive target or entered into a binding agreement as of the filing date. Management expected to fund reporting and acquisition-related costs through additional advances, equity financing, or other investment, but no party was contractually required to provide additional funding.
After the fiscal year-end, the Company disclosed a proposed merger with Compass Therapeutics LLC, a clinical-stage biotechnology company focused on monoclonal and multispecific antibody therapeutics. The proposed transaction contemplated Compass equity holders receiving more than 95% of the post-merger common stock before a potential private placement, resulting in a change of control. The merger agreement and private placement documentation had not been executed, and completion was subject to conditions precedent, including financing. There was no assurance that either transaction would be completed.
The independent auditor reported substantial doubt about the Company’s ability to continue as a going concern because of recurring losses, negative working capital, and stockholders’ deficit. Management’s plan depended on additional related-party borrowings and/or financing associated with a reverse merger. The financial statements included no adjustments that might result if the Company could not continue as a going concern.
- COVID-19 could impair the search for, negotiation of, and ability to complete a business combination, and could adversely affect any eventual target.
- The Company faced significant competition from better-capitalized entities seeking acquisition targets.
- A transaction could substantially dilute existing shareholders and transfer control to the target company’s owners.
- Management had limited time and resources and was involved with other blank-check companies, creating potential conflicts of interest.
- The Company had no established milestones or timetable for completing a transaction.
- The Company’s NOL carryforwards were approximately $109,000, but the related deferred tax asset was fully offset by a valuation allowance.
Investor Verification Items
- Verify the filing identity and period: the source is Olivia Ventures, Inc., fiscal year ended March 31, 2020, rather than Compass Therapeutics, Inc. or 2019 Q4.
- Confirm whether the proposed Compass merger agreement was ultimately executed and whether the merger and contemplated private placement closed.
- Review subsequent Form 8-K filings, merger documents, financing terms, ownership changes, and any new share issuances.
- Assess the going-concern uncertainty, available cash of $3,745, and reliance on additional related-party funding.
- Review the $111,817 related-party liability, including the interest rate, repayment conditions, and potential default provisions.
- Evaluate dilution and change-of-control implications for the existing 5,000,000 shares.
- Confirm the impact of COVID-19 and any delays or changes to the proposed business combination.